Advancing innovation in drug and alcohol addiction healthcare

[{"label":"Ineligible Leads","value":"Academic institutions, RTOs, charities, CICs and non profit organisations cannot lead."},{"label":"Application Limit","value":"A business can lead one application and collaborate in two further applications. If not leading, it can collaborate in unlimited applications."},{"label":"Research Category","value":"Industrial research only"},{"label":"Substances in Scope","value":"Opioids. Stimulants including cocaine and methamphetamine. Cannabis. GHB. Ketamine. Benzodiazepines. Gabapentinoids."},{"label":"Subcontractors","value":"Allowed. Overseas subcontractors must be justified. Lower cost alone is not sufficient reason."},{"label":"Subsidy Scheme","value":"Provided under the Subsidy Control Act 2022. Classified as a Subsidy. Not part of Minimal Financial Assistance."},{"label":"Sanctions Rule","value":"Funding will not be provided where it breaches UK sanctions."},{"label":"Animal Research Rule","value":"Projects involving animals must comply with UKRI animal welfare guidance."},{"label":"Interview Stage","value":"Shortlisted applicants invited to interview between 20 July 2026 and 24 July 2026. Presentation required. Interview score supersedes initial score."},{"label":"Key Requirements","value":"Must engage people with lived experience. Must engage treatment or service providers. Must define regulatory pathway. Must include commercialisation plan. Must test in real world settings."},{"label":"Renewal Rules","value":"A previously assessed application can be resubmitted once if not materially different."},{"label":"Important Notes","value":"Collaboration only competition. Cannot apply to both strands with the same project. Project must not start before Grant Offer Letter approval. Funding subject to sufficient high quality applications."}]